Da Yang, MD, PhD was awarded an NIH grant to study how a newly discovered gene (EPIC1) links to the breast cancer onset and progression.

EPIC1 belongs in the class of non-coding RNA genes and is critical for the function of the oncoprotein, MYC, that plays a critical role in breast cancer. Yang will use in vivo and in vitro breast cancer models to determine if inhibition of EPIC1 will lead to robust suppression of tumor growth. His work may lead to the development of new cancer therapies for patients that currently do not have effective treatments.

Yang is an assistant professor in the Pharmaceutical Department at PittPharmacy.


Leave a comment